所有图片(1)
别名:
1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt
经验公式（希尔记法）:
C8H7N2NaO3S
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
H2O: >5 mg/mL
创始人
Eisai
SMILES字符串
[Na]NS(=O)(=O)Cc1noc2ccccc12
InChI
1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1
InChI key
ZVBIRPKGWOVBLG-UHFFFAOYSA-N
基因信息
human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
生化/生理作用
Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO).
特点和优势
This compound was developed by Eisai. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
S Dupont et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 29-35 (2012-11-01)
Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe
Kouji Fukuyama et al.
Pharmaceuticals (Basel, Switzerland), 13(6) (2020-06-11)
Recent studies using the genetic partial epilepsy model have demonstrated that hyperfunction of astroglial hemichannels contributes to pathomechanism of epileptic seizure. Therefore, to explore the novel anticonvulsive mechanisms, the present study determined the effects of voltage-dependent Na+ channel (VDSC)-inhibiting anticonvulsants
D Marazziti et al.
European review for medical and pharmacological sciences, 16(15), 2102-2107 (2013-01-03)
Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles
Andrea Romigi et al.
Epilepsy & behavior : E&B, 26(2), 170-174 (2013-01-15)
The purpose of this study was to evaluate the effects of zonisamide (ZNS) as adjunctive therapy on sleep-wake cycle and daytime somnolence in adult patients affected by focal epilepsy. Thirteen patients affected by focal epilepsy were recruited to undergo a
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门